FDA clears first ever 'biosimilar' drug, paves way for cheaper drugs
New drug Zarxio helps prevent infections in cancer patients undergoing chemo
New York
THE US Food and Drug Administration (FDA) has approved the first so-called biosimilar drug for use in the US, paving the way for less expensive alternatives to an entire class of complex and costly drugs.
The drug, called Zarxio, produced by Sandoz, helps prevent infections in cancer patients receiving chemotherapy. It is a close copy of an existing medication called Neupogen, made by Amgen.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO